ROIV Roivant Sciences
- 11.380
- -0.220-1.90%
- 11.600
- +0.220+1.93%
Roivant Sciences News
Buy Rating Justified by Roivant Sciences' Strategic Positioning and Promising Drug Pipeline
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
Roivant Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating
Buy Rating Affirmed for Roivant Sciences Amid Brepocitinib Success and Strategic Share Repurchase Program
Roivant Sciences Analyst Ratings
Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
Truist Securities Reiterates Buy on Roivant Sciences, Maintains $23 Price Target
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)
TD Cowen Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
Analysis
Price Target
No Data
